The purpose of this study was to determine the dose enhancement factor (DEF) of gold nanoparticles in a dosimeter gel and construct percentage depth dose curves, using the Optical CT system and the Monte Carlo simulation model, to determine the effect of increasing the dose caused by increasing the concentration of gold nanoparticles at depths in the gel.

The Magic-f Gel was made based on the relevant protocol in the physics lab. To determine the amount of the increase in the absorbed dose, the gold nanoparticles were added to the gel and irradiated. An increase in the dose after adding nanoparticles to the gel vials was estimated both with the Optical CT system and by the Monte Carlo simulation method.

Dose enhancement curves for doses of 2, 4 and 6 Gy were prepared for gel vials without adding nanoparticles, and nanoparticle gels at concentrations 0·17, 3 and 6 mM. Also, the DEF was estimated. For the 0·17 mM molar gel, the DEF for 2, 4 and 6 Gy was 0·7, 0·743 and 0·801, respectively. For the 3 mM gel, it was 1·98, 2·5 and 2·2, and for the 6 mM gel, it was 37·4, 4·24 and 4·71, respectively.

The enhancement of the dose after adding gold nanoparticles was confirmed both by experimental data and by simulation data.

Recent investigations demonstrate a strong potential for cobalt-60 (Co-60)-based teletherapy. The influence of the lower energy and penetration of a cobalt-60 beam compared with linear accelerator beams is negligible for intensity-modulated radiotherapy.

The aim of this research is to investigate source head fluence modulation in cobalt-60 teletherapy by using a three-dimensional (3D) physical compensator and secondary collimator jaw motion.

The Oncentra treatment planning system was used to develop three hypothetical plans by secondary collimator jaw motion. A clinical MDS Nordion Equinox 80 cobalt-60 teletherapy unit was used to acquire conventional water phantom beam characteristics. Fluence modulation experiments were executed at 5·0 cm depth in a PTW universal intensity-modulated radiation therapy (IMRT) verification phantom using calibrated Gafchromic external beam therapy 2 (EBT2) and RTQA2-1010 film batches. Gafchromic EBT2 film was used to sample intensity maps generated by secondary collimator jaw motion, yet Gafchromic RTQA2-1010 film sampled maps from the 3D physical compensator. The solid-state drives used were 75·0 and 74·3 cm for the Gafchromic EBT2 and Gafchromic RTQA2-1010 film measurements.

A 2D gamma index analysis was coded to compare EBT2 film measurements with Digital Imaging and Communications in Medicine data. This analysis was also used to verify film measurements versus Monte-Carlo simulations.

Lateral beam profiles generated from water phantom measurements were used to establish source head fluence modulation on the film measurements. The source head fluence of a cobalt-60 teletherapy beam could be modulated by secondary collimator jaw motion and using a 3D physical compensator.

The success of radiation therapy for cancer patients is dependent on the ability to deliver a total tumouricidal radiation dose capable of eradicating all cancer cells within the clinical target volume, however, the radiation dose tolerance of the surrounding healthy tissues becomes the main dose-limiting factor. The normal tissue adverse effects following radiotherapy are common and significantly impact the quality of life of patients. The likelihood of developing these adverse effects following radiotherapy cannot be predicted based only on the radiation treatment parameters. However, there is evidence to suggest that some common genetic variants are associated with radiotherapy response and the risk of developing adverse effects. Radiation genomics is a field that has evolved in recent years investigating the association between patient genomic data and the response to radiation therapy. This field aims to identify genetic markers that are linked to individual radiosensitivity with the potential to predict the risk of developing adverse effects due to radiotherapy using patient genomic information. It also aims to determine the relative radioresponse of patients using their genetic information for the potential prediction of patient radiation treatment response.

This paper reports on a review of recent studies in the field of radiation genomics investigating the association between genomic data and patients response to radiation therapy, including the investigation of the role of genetic variants on an individual’s predisposition to enhanced radiotherapy radiosensitivity or radioresponse.

The potential for early prediction of treatment response and patient outcome is critical in cancer patients to make decisions regarding continuation, escalation, discontinuation, and/or change in treatment options to maximise patient survival while minimising adverse effects and maintaining patients’ quality of life.

Cancer of the vulva is rare, it is a disease commonly diagnosed in elderly women, however, the incidence in younger women is rising. Many patients diagnosed and treated for vulval cancer face physical, social, sexual and psychological challenges. It is essential that therapy radiographers and members of the wider multidisciplinary team understand such challenges in order to provide patient centred care.

This review aims to highlight the key psycho-social issues experienced by patients with cancer of the vulva, identifying implications for practice in order to improve the holistic care for this patient group.

A search of English literature was performed using Medline, Pubmed, CINAHL and PsycINFO. Search terms included, vulva or vulval cancer, psychosocial, psychosexual impact and quality of life. Articles were excluded if they focussed on cancers other than gynaecological and vulval cancers.

Although there are numerous reports on the psychological and psychosocial problems faced by gynaecological cancer patients; there was a paucity of literature pertaining to patients with cancer of the vulva, this is consistent with previous research. Studies show a significant negative, psychosocial impact experienced by these women. Common themes being isolation, loneliness, stigmatisation and lack of information for patients and their carers, themes spanning over three decades. Nevertheless, it is important to be aware of the findings from recent studies consistent with patient’s needs, highlighting that listening to women’s narratives on living with cancer of the vulva is essential if we are to help with the psychosocial issues experienced by these women. They underline a necessity to raise awareness among healthcare professionals and the general public, to improve holistic support for this particular group of women. This is particularly important in the radiotherapy setting as many of these women undergo lengthy courses of treatment and the appropriately trained therapeutic radiographer can play a vital role in addressing the physical and psychosocial problems.

Breast intraoperative radiotherapy (IORT) is a partial irradiation technique that delivers a single fraction of radiation dose to the tumour bed during surgery. The use of this technique is increasing (especially in the Middle East), and therefore, it is essential to have a comprehensive approach to this treatment modality. The aim of this study is to conduct a literature review on available IORT modalities during breast irradiation as well as dedicated IORT machines and associated treatment procedures. The main IORT trials and corresponding clinical outcomes are also studied.

A computerised search was performed through MEDLINE, PubMed, PubMed Central, ISI web of knowledge and reference list of related articles.

IORT is now feasible through using two main modalities, including low-kilovolt IORT and intraoperative electron radiotherapy (IOERT). The dedicated machines employed and treatment procedure for mentioned modalities are quite different. The outcomes of implemented clinical trials showed that IORT is not inferior to external beam radiotherapy (EBRT) in specifically selected and well-informed patients and can be considered as an alternative to EBRT.

Although the clinical outcomes of introduced IORT methods are comparable, but based on the review results, it could be said that IOERT is the most effective technical method, in view of the treatment time and dose uniformity concepts. The popularity of IORT is mainly due to the distinguished obtained results during breast cancer treatment. Despite the presence of some technical challenges, it is expected that the IORT technique will become more widespread in the immediate future.

In advanced radiotherapy techniques such as intensity-modulated radiation therapy (IMRT), the quality assurance (QA) process is essential. The aim of the study was to assure the treatment planning dose delivered during delivery of complex treatment plans. The QA standard is to perform patient-specific comparisons between planned doses and doses measured in a phantom.

The Delta 4 phantom (Scandidos, Uppsala, Sweden) has been used in this study. This device consists of diode matrices in two orthogonal planes inserted in a cylindrical acrylic phantom. Each diode is sampled per beam pulse so that the dose distribution can be evaluated on segment-by-segment, beam-by-beam, or as a composite plan from a single set of measurements. Ninety-five simple and complex radiotherapy treatment plans for different pathologies, planned using a treatment planning system (TPS) were delivered to the QA device. The planned and measured dose distributions were then compared and analysed. The gamma index was determined for different pathologies.

The evaluation was performed in terms of dose deviation, distance to agreement and gamma index passing rate. The measurements were in excellent agreement between with the calculated dose of the TPS and the QA device. Overall, good agreement was observed between measured and calculated doses in most cases with gamma values above 1 in >95% of measured points. Plan results for each test met the recommended dose goals.

The delivery of IMRT and volumetric-modulated arc therapy (VMAT) plans was verified to correspond well with calculated dose distributions for different pathologies. We found the Delta 4 device is accurate and reproducible. Although Delta4 appears to be a straightforward device for measuring dose and allows measure in real-time dosimetry QA, it is a complex device and careful quality control is required before its use.